Neuropathix, Inc. Reveals Visual Identity to Coincide With Its Mission for Socially Responsible Pain Management
DOYLESTOWN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Neuropathix, Inc. ("Neuropathix" or the “Company”) (OTCQB: NPTX), formerly Kannalife, Inc., is a socially responsible pain management life sciences company. For the past ten years, Neuropathix has discovered, developed and patented a global intellectual property estate of novel new monotherapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants.
Coinciding with its new brand identity and name change, the Company has updated its logo and visual identity to reflect the Company’s extensive life sciences research in cannabinoid therapeutics, drug discovery and current goal of bringing much-needed potent, non-opioid alternatives for the treatment of chronic and neuropathic pain to market.
As a part of this rebranding, the Kannalife brand name, Kannalife, Inc., and Kannalife Sciences, Inc. will remain as subsidiaries of Neuropathix.
“One of our biggest challenges in the past ten years has been in dealing with the disconnect from the markets in terms of corporate identity. When we started out as a cannabinoid therapeutics drug discovery company in 2010, we set out to try and find a place and potential for cannabinoid therapeutics like CBD as a pharmaceutical API for use in the clinic. That discipline as a pharmaceutical company has never changed and remains true to this day. Neuropathix embodies our life sciences achievements and perfectly describes our corporate mission and our goal to bring pharmaceutical grade medicines for neurodegenerative and oxidative stress-related diseases,” said Dean Petkanas, CEO of Neuropathix.
Neuropathix is a well-known pioneer in cannabinoid-like therapeutics. The Company has been consistently covered by global news over the last decade. Additionally, its scientific findings have been published in several highly respected peer reviewed journals such as the American Chemical Society Medicinal Chemistry Letters and the Journal of Molecular Neuroscience.
This Company’s spotlight on potent, non-opioid alternatives for the treatment of neuropathic pain can be seen in its phase 1 NIH study grant completed in late 2019. That preclinical study confirmed the ability of KLS-13019 to prevent and reverse neuropathic pain in animal models and stands as a strong candidate as a potential treatment for neuropathic pain and the reduction of the use of opioids.
To coincide with this rebranding, the Company will be releasing a new corporate website at www.neuropathix.com.
About Neuropathix
Neuropathix, Inc., formerly Kannalife, Inc. ("Neuropathix"), is a socially responsible pain management life sciences company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from neurodegenerative and oxidative stress related diseases. The Company's leading drug candidate KLS-13019, a non-opioid solution for chronic and neuropathic pain, has shown promise in pre-clinical studies to prevent and reverse neuropathic pain in the model to treat chemotherapy-induced peripheral neuropathy (CIPN). In addition to CIPN studies, the Company's early research also focused on neuroprotection in the model for overt hepatic encephalopathy (OHE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain.
Since 2010, Neuropathix has discovered, developed and patented a global intellectual property estate of novel new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants.
Neuropathix was the only company to hold an exclusive license with National Institutes of Health - Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent").
Atopidine™ is Neuropathix novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.
KLS-13019 is Neuropathix leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine™ have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.
The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as overt hepatic encephalopathy (OHE), chronic pain from neuropathies like CIPN, and neurodegenerative diseases like chronic traumatic encephalopathy (CTE), and mild traumatic brain injury (mTBI). Neuropathix conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Neuropathix, visit www.neuropathix.com and the Company’s Twitter page at @neuropathix.
Forward-Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations:
Kathryn Reinhardt
Account Supervisor
CMW Media
P. 858-264-6600
E: kathryn@cmwmedia.com
www.cmwmedia.com
Investor Relations:
Scott Gordon, Managing Director of CORE IR
P: 516-222-2560
E: scottg@coreir.com
www.coreir.com
